Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Tetraphase Wins BARDA Antibiotic Contract | Contract Pharma

What are you searching for?

Sign in
Breaking News

Tetraphase Wins BARDA Antibiotic Contract

Contract includes clinical studies, manufacturing, associated regulatory activities

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biomedical Advanced Research and Development Authority (BARDA) has awarded Tetraphase Pharmaceuticals a contract with a total value of $67 million for the development of TP-434, a potent new antibiotic effective against multidrug-resistant gram-negative pathogens. TP-434 is Tetraphase’s lead product candidate. Tetraphase will be work on this contract with CUBRC, Inc., based in Buffalo, NY.

The contract includes preclinical efficacy and toxicology studies, clinical studies, manufacturing, and associated regulatory activities for TP-434 as a potential treatment of inhalational disease caused by Bacillus anthracis, Francisella tularensis and Yersinia pestis. Also, TP-434 is being developed as a potential therapeutic agent for serious hospital infections, including those caused by multidrug-resistant aerobic and/or anaerobic gram-negative and gram-positive pathogens.

“BARDA’s award covering the development of TP-434 brings the total federal funding in support of the development of Tetraphase’s antibiotics to more than $100 million,” said Guy Macdonald, president and chief executive officer of Tetraphase. “Tetraphase and CUBRC are proud to play an important role in addressing the global concerns of bioterrorism and antibiotic resistance via the development of potential solutions to these growing threats to human health.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics